| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer (NCT05985109) | Peking University Cancer Hospital & Institute | 2023-10-26 |
| KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade (NCT06099821) | Peking University Cancer Hospital & Institute | 2023-10-25 |
| Registry Study in MSI/dMMR Solid Tumors (NCT06004713) | Peking University Cancer Hospital & Institute | 2023-10-07 |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma (NCT05985707) | Peking University Cancer Hospital & Institute | 2023-08-15 |
| Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT05955209) | Peking University Cancer Hospital & Institute | 2023-08-01 |
| Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy (NCT05985278) | Peking University Cancer Hospital & Institute | 2023-07-06 |
| To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases (NCT05889325) | Peking University Cancer Hospital & Institute | 2023-07-01 |
| Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC (NCT05917431) | Peking University Cancer Hospital & Institute | 2023-06-01 |
| Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients (NCT06256315) | Peking University Cancer Hospital & Institute | 2023-06-01 |
| Outcomes of Endoscopic Operation in COVID-19 Infection: Cohort Study. (NCT05685914) | Peking University Cancer Hospital & Institute | 2023-05-31 |
| The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases (NCT05877001) | Peking University Cancer Hospital & Institute | 2023-05-30 |
| Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer (NCT07018427) | Peking University Cancer Hospital & Institute | 2023-05-01 |
| The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon Cancer (NCT05859581) | Peking University Cancer Hospital & Institute | 2023-04-02 |
| Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) (NCT06229041) | Peking University Cancer Hospital & Institute | 2023-03-29 |
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma (NCT05789043) | Peking University Cancer Hospital & Institute | 2023-03-21 |
| Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma (NCT05816863) | Peking University Cancer Hospital & Institute | 2023-03-01 |
| Computation Prediction of Drug Response Based on Omics Data (NCT05833802) | Peking University Cancer Hospital & Institute | 2023-02-15 |
| Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors (NCT05579275) | Peking University Cancer Hospital & Institute | 2023-02-06 |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma (NCT05656144) | Peking University Cancer Hospital & Institute | 2023-02-01 |
| Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma (NCT05590221) | Peking University Cancer Hospital & Institute | 2023-01-03 |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma (NCT05862181) | Peking University Cancer Hospital & Institute | 2023-01-01 |
| Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (NCT06081777) | Peking University Cancer Hospital & Institute | 2022-11-25 |
| Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer (NCT05529615) | Peking University Cancer Hospital & Institute | 2022-11-01 |
| Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma (NCT05478473) | Peking University Cancer Hospital & Institute | 2022-10-27 |
| Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer (NCT05577442) | Peking University Cancer Hospital & Institute | 2022-10-20 |
| Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma (NCT05512481) | Peking University Cancer Hospital & Institute | 2022-09-13 |
| A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer (NCT05380024) | Peking University Cancer Hospital & Institute | 2022-08-17 |
| PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor (NCT05803746) | Peking University Cancer Hospital & Institute | 2022-07-15 |
| Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients (NCT05758116) | Peking University Cancer Hospital & Institute | 2022-07-07 |
| CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors (NCT05436093) | Peking University Cancer Hospital & Institute | 2022-06-23 |
| Attitudes and Technical Maneuvers Regarding Enterostomy Management and Stoma Creation Among Surgeons (NCT06735729) | Peking University Cancer Hospital & Institute | 2022-06-19 |
| Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma (NCT05411250) | Peking University Cancer Hospital & Institute | 2022-06-01 |
| Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance (NCT05933863) | Peking University Cancer Hospital & Institute | 2022-03-29 |
| Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy (NCT05406206) | Peking University Cancer Hospital & Institute | 2022-02-25 |
| Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC (NCT05969184) | Peking University Cancer Hospital & Institute | 2021-12-12 |
| PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor (NCT05156515) | Peking University Cancer Hospital & Institute | 2021-12-09 |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma (NCT05104801) | Peking University Cancer Hospital & Institute | 2021-11-01 |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NCT05104788) | Peking University Cancer Hospital & Institute | 2021-10-25 |
| Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (NCT05132218) | Peking University Cancer Hospital & Institute | 2021-10-19 |
| To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma (NCT05051865) | Peking University Cancer Hospital & Institute | 2021-10-09 |
| Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis (NCT05070221) | Peking University Cancer Hospital & Institute | 2021-10-01 |
| Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis (NCT05068453) | Peking University Cancer Hospital & Institute | 2021-10-01 |
| 68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy (NCT05000372) | Peking University Cancer Hospital & Institute | 2021-09-22 |
| cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC (NCT05025592) | Peking University Cancer Hospital & Institute | 2021-09-10 |
| PD-L1 Targeting Molecular Imaging of Solid Tumors (NCT04629326) | Peking University Cancer Hospital & Institute | 2021-07-20 |
| Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma (NCT07700836) | Peking University Cancer Hospital & Institute | 2021-07-01 |
| CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors (NCT04883970) | Peking University Cancer Hospital & Institute | 2021-05-13 |
| Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab (NCT05188495) | Peking University Cancer Hospital & Institute | 2021-05-10 |
| Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors (NCT04764084) | Peking University Cancer Hospital & Institute | 2021-04-01 |
| Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma (NCT04479527) | Peking University Cancer Hospital & Institute | 2021-04-01 |
| Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC (NCT04629027) | Peking University Cancer Hospital & Institute | 2021-03-03 |
| Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NCT04137588) | Peking University Cancer Hospital & Institute | 2021-03-03 |
| Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut (NCT05274438) | Peking University Cancer Hospital & Institute | 2021-01-26 |
| [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients (NCT04693169) | Peking University Cancer Hospital & Institute | 2021-01-15 |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma (NCT04622566) | Peking University Cancer Hospital & Institute | 2020-12-30 |
| A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. (NCT04606303) | Peking University Cancer Hospital & Institute | 2020-12-18 |
| PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer (NCT04560725) | Peking University Cancer Hospital & Institute | 2020-10-22 |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC (NCT04597970) | Peking University Cancer Hospital & Institute | 2020-10-20 |
| The Role of TCM on ERAS of Rectal Cancer Patients (NCT04749381) | Peking University Cancer Hospital & Institute | 2020-09-28 |
| Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI (NCT04555642) | Peking University Cancer Hospital & Institute | 2020-09-15 |
| The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (NCT04542837) | Peking University Cancer Hospital & Institute | 2020-09-11 |
| The Molecular Imaging Research of F-18 Labeled DX600 PET Probe (NCT04542863) | Peking University Cancer Hospital & Institute | 2020-09-11 |
| Research for the Molecular Imaging of the HER2 Targeting Tracer (NCT04547309) | Peking University Cancer Hospital & Institute | 2020-09-07 |
| 99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients (NCT04591652) | Peking University Cancer Hospital & Institute | 2020-09-01 |
| HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma (NCT06184841) | Peking University Cancer Hospital & Institute | 2020-06-18 |
| Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients (NCT04422457) | Peking University Cancer Hospital & Institute | 2020-06-13 |
| To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ultrasound-guided Radiofrequency Ablation (NCT04417010) | Peking University Cancer Hospital & Institute | 2020-06-01 |
| Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study (NCT04462965) | Peking University Cancer Hospital & Institute | 2020-05-30 |
| Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer (NCT04405206) | Peking University Cancer Hospital & Institute | 2020-05-25 |
| Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen (NCT04340401) | Peking University Cancer Hospital & Institute | 2020-05-25 |
| Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of (NCT05374044) | Peking University Cancer Hospital & Institute | 2020-05-18 |
| The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma (NCT04357509) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma (NCT04367948) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma (NCT04397770) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy (NCT05229029) | Peking University Cancer Hospital & Institute | 2020-04-02 |
| A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer (NCT04264936) | Peking University Cancer Hospital & Institute | 2020-02-15 |
| Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC (NCT04303130) | Peking University Cancer Hospital & Institute | 2019-12-31 |
| Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (NCT03941795) | Peking University Cancer Hospital & Institute | 2019-11-11 |
| Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions (NCT04170257) | Peking University Cancer Hospital & Institute | 2019-10-18 |
| Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer (NCT04750772) | Peking University Cancer Hospital & Institute | 2019-10-16 |
| Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas (NCT05390632) | Peking University Cancer Hospital & Institute | 2019-10-15 |
| The Performance of Multi-tracer Multimodality PET in Lymphoma (NCT05004961) | Peking University Cancer Hospital & Institute | 2019-09-15 |
| Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma (NCT04047953) | Peking University Cancer Hospital & Institute | 2019-09-10 |
| Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma (NCT04180995) | Peking University Cancer Hospital & Institute | 2019-08-06 |
| Research for the Molecular Imaging of the PD-L1 Targeting Tracer (NCT04304066) | Peking University Cancer Hospital & Institute | 2019-08-06 |
| A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC (NCT04023617) | Peking University Cancer Hospital & Institute | 2019-07-08 |
| Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases (NCT06404593) | Peking University Cancer Hospital & Institute | 2019-06-18 |
| Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma (NCT04197882) | Peking University Cancer Hospital & Institute | 2019-05-27 |
| Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma (NCT04206358) | Peking University Cancer Hospital & Institute | 2019-05-13 |
| Nab-PCE vs PC for MM After Failure of Anti-PD-1 (NCT03917069) | Peking University Cancer Hospital & Institute | 2019-03-23 |
| PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma (NCT03955354) | Peking University Cancer Hospital & Institute | 2019-03-05 |
| Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer (NCT04296240) | Peking University Cancer Hospital & Institute | 2019-03-01 |
| Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer (NCT04192331) | Peking University Cancer Hospital & Institute | 2019-02-21 |
| Preliminary Study on Eye Features of Patients With Malignant Tumors (NCT04224298) | Peking University Cancer Hospital & Institute | 2019-02-01 |
| Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy (NCT03613142) | Peking University Cancer Hospital & Institute | 2019-01-01 |
| Study on the Applicability of CCR Criteria in Rectal Cancer (NCT06794099) | Peking University Cancer Hospital & Institute | 2019-01-01 |
| Anlotinib in Treatment of Recurrent Small Cell Lung Cancer (NCT03732846) | Peking University Cancer Hospital & Institute | 2018-11-01 |
| Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC (NCT03708783) | Peking University Cancer Hospital & Institute | 2018-07-01 |
| Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT04408859) | Peking University Cancer Hospital & Institute | 2018-04-17 |
| Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography (NCT03708978) | Peking University Cancer Hospital & Institute | 2018-04-05 |